Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 201027 Jan 2011 • by Natalie Aster
“GlobalData analysis finds that the global colorectal cancer therapeutics market is very attractive and has primarily been driven by the growth in patient volume and the annual cost of therapy. Between 2001 and 2009, the market grew at a rate of 27.6%.GlobalData analysis found that, in 2009, the global colorectal cancer therapeutics market was worth $7.0 billion. By 2020, the market is expected to be worth $8.8 billion, indicating a Compound Annual Growth Rate (CAGR) of 2.1% between 2009 and 2020.”
The report “Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010” by GlobalData provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global colorectal cancer therapeutics market. The report analyses the treatment usage patterns in the global colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. It quantifies the unmet need in the global colorectal cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.
Key benefits of the report:
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast;
- An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020;
- Analysis of the current and future market competition in the Global Colorectal and Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis.
Published: October 2010
Price: US$ 15,000.00 US$ 13,500.00
Offer valid until January 31, 2011!
The current competition in the global colorectal cancer therapeutics market is weak, as none of the drugs are effective enough to address the high unmet needs that exist in the market. In 2009, the unmet need in the colorectal cancer market was quantified and estimated at $4.0 billion. GlobalData analysis suggests that approximately 57% of the global colorectal cancer therapeutics market is underserved. There are about eight drugs including targeted therapies currently in the market. The colorectal cancer therapeutics pipeline is strong. Currently, about 246 research and development activities including preclinical trials are being conducted on 96 molecules.
More information can be found in the report “Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010” by GlobalData.
To order the report or ask for sample pages contact firstname.lastname@example.org